30-Jan-2026
$75 Million Institutional Investment Bolsters Altimmune's Phase 3 Ambitions in Liver Disease
Market Chameleon (Fri, 30-Jan 3:27 AM ET)
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Globe Newswire (Thu, 29-Jan 5:54 PM ET)
Altimmune Announces $75 Million Registered Direct Equity Offering
TipRanks (Wed, 28-Jan 5:49 PM ET)
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline
TipRanks (Wed, 28-Jan 3:09 AM ET)
Altimmune prices $75M direct offering
Seeking Alpha News (Tue, 27-Jan 11:39 PM ET)
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
Globe Newswire (Tue, 27-Jan 9:25 PM ET)
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Globe Newswire (Mon, 5-Jan 7:30 AM ET)
Market Chameleon (Mon, 22-Dec 5:19 AM ET)
Market Chameleon (Fri, 19-Dec 2:06 AM ET)
Globe Newswire (Fri, 19-Dec 6:30 AM ET)
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Altimmune trades on the NASDAQ stock market under the symbol ALT.
As of January 30, 2026, ALT stock price climbed to $5.60 with 5,811,030 million shares trading.
ALT has a beta of 0.71, meaning it tends to be less sensitive to market movements. ALT has a correlation of 0.01 to the broad based SPY ETF.
ALT has a market cap of $701.30 million. This is considered a Small Cap stock.
Last quarter Altimmune reported $5,000 in Revenue and -$.21 earnings per share. This beat revenue expectation by $4,440 and exceeded earnings estimates by $.07.
In the last 3 years, ALT traded as high as $15.95 and as low as $2.09.
The top ETF exchange traded funds that ALT belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
ALT has underperformed the market in the last year with a return of -20.0%, while SPY returned +15.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ALT shares. However, ALT has outperformed the market in the last 3 month and 2 week periods, returning +37.6% and +32.1%, while SPY returned +2.1% and 0.0%, respectively. This indicates ALT has been having a stronger performance recently.
ALT support price is $4.77 and resistance is $5.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALT shares will trade within this expected range on the day.